ZIM
EGRX

Zacks Investment Management’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

Zacks Investment Management’s Portfolio EGRX Stock Details EGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-36,222
Closed -$2.05M – 607
2019
Q3 		$2.05M Buy
+36,222
New +$2.04M 0.04% 253

Other funds holding EGRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
PWAM
Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
HEC
Hudson Executive Capital New York $151M AUM 60.14% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM

Zacks Investment Management's EGRX Position: Q4 2019 in Review

Zacks Investment Management sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q4 2019, closing a stake of 36,222 shares — an estimated $2.05M sold.

Zacks Investment Management first reported a position in EGRX in Q3 2019 and held it in 1 quarter. The position peaked at $2.05M in Q3 2019. 176 funds tracked by Wall St. Rank hold EGRX as of Q4 2019.

  • Zacks Investment Management reported no remaining Eagle Pharmaceuticals, Inc. position as of Q4 2019 after selling out during the quarter.
  • Zacks Investment Management sold 36,222 Eagle Pharmaceuticals, Inc. shares in Q4 2019, an estimated $2.05M.
  • Zacks Investment Management first reported a position in Eagle Pharmaceuticals, Inc. in Q3 2019 and held it in 1 quarter.
  • Zacks Investment Management's Eagle Pharmaceuticals, Inc. position peaked at $2.05M in Q3 2019.
  • 176 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q4 2019.

Based on Zacks Investment Management's 13F filing for Q4 2019, filed 14 Feb 2020.